Syros Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Syros Pharmaceuticals is a daily existence sciences organization that is centered around treating infection by planning quality administrative circuits and balancing the elements that direct quality articulation. Syros has spearheaded world-driving quality control examination and medication disclosure capacities with a demonstrated capacity to coordinate illness science and genomic information - a capability that isn't very much addressed in drug R&D. Key to the Syros approach is a restrictive foundation of painstakingly coordinated measure innovations, bioinformatics, and biologic bits of knowledge created by individuals from Syros' senior initiative. While this logical methodology has applications in numerous remedial regions, Syros has shown achievement at first in oncology, where it might help address various neglected clinical requirements.
Syros Pharmaceuticals has raised $130M across 1 funding round on record, the most recent a Post-IPO Equity of $130M announced in Jul 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Syros Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jul 2022.
Syros Pharmaceuticals Funding Rounds
Syros Pharmaceuticals Founders and Leadership Team
Contact details for the Syros Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Syros Pharmaceuticals Funding Compared to Other Biotechnology Startups
Syros Pharmaceuticals' latest round of $130M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Syros Pharmaceuticals in Biotechnology and Watertown
Companies Similar to Syros Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Syros Pharmaceuticals Funding FAQs
What does Syros Pharmaceuticals do?
Syros Pharmaceuticals is a daily existence sciences organization that is centered around treating infection by planning quality administrative circuits and balancing the elements that direct quality articulation. Syros has spearheaded world-driving quality control examination and medication disclosure capacities with a demonstrated capacity to coordinate illness science and genomic information - a capability that isn't very much addressed in drug R&D. Key to the Syros approach is a restrictive foundation of painstakingly coordinated measure innovations, bioinformatics, and biologic bits of knowledge created by individuals from Syros' senior initiative. While this logical methodology has applications in numerous remedial regions, Syros has shown achievement at first in oncology, where it might help address various neglected clinical requirements.
How much funding has Syros Pharmaceuticals raised?
Syros Pharmaceuticals has raised $130M across 1 round on record. The most recent is a Post-IPO Equity of $130M announced in Jul 2022.
When did Syros Pharmaceuticals last raise funding?
Syros Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $130M, announced in Jul 2022.
Who is the CEO of Syros Pharmaceuticals?
Nancy Simonian is listed as CEO at Syros Pharmaceuticals.
Where is Syros Pharmaceuticals headquartered?
Syros Pharmaceuticals is based in Watertown, Massachusetts, United States.
How many employees does Syros Pharmaceuticals have?
Syros Pharmaceuticals is in the 101-250 employee band.
How does Syros Pharmaceuticals' funding compare to other Biotechnology startups?
Syros Pharmaceuticals' latest round of $130M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Syros Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Syros Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.